Ptc Therapeutics (PTCT) Non-Current Deffered Revenue (2012 - 2020)

Ptc Therapeutics' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2020.

• In Q1 2020, Non-Current Deffered Revenue fell 80.03% year-over-year to $1.8 million; the TTM figure through Mar 2020 stood at $1.8 million (down 80.03% YoY), while the FY2019 annual figure was $3.4 million, down 64.87% from the prior year.
• Non-Current Deffered Revenue was $1.8 million for Q1 2020 at Ptc Therapeutics, down from $3.4 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $11.2 million in Q3 2018 to a low of $1.6 million in Q4 2016.
• Historically, Non-Current Deffered Revenue has averaged $6.4 million across 5 years, with a median of $7.2 million in 2017.
• The sharpest annual moves came in 2017 and 2020: Non-Current Deffered Revenue soared 401.2% in 2017, then tumbled 80.03% in 2020.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $1.6 million in 2016, then jumped by 401.2% to $8.0 million in 2017, then rose by 22.23% to $9.7 million in 2018, then sank by 64.87% to $3.4 million in 2019, then sank by 48.23% to $1.8 million in 2020.
• The last three Non-Current Deffered Revenue figures came in at $1.8 million (Q1 2020), $3.4 million (Q4 2019), and $5.5 million (Q3 2019), per Business Quant data.